{"Clinical Trial ID": "NCT01340300", "Intervention": ["INTERVENTION 1:", "\u2022 Exercise training with Metformin", "Training with an exercise physiologist with oral metformin", "\u2022 Exercise training plus metformin: Two supervised exercise sessions per week. QD oral metformin for 2 weeks, then IDB", "INTERVENTION 2:", "Exercise training", "Training in exercise with an exercise physiologist", "Training: two supervised exercise sessions per week"], "Eligibility": ["Incorporation criteria:", "Histologically confirmed test of stage I-III colorectal or breast cancer", "\u2022 Complete surgical resection with curative sub-intention and complete all adjuvant treatments (if indicated) at least 2 months prior to registration", "Note: Subjects with breast cancer on hormonal or trastuzumab therapy only and subjects with complementary colorectal cancer who are not considered cytotoxic chemotherapy (including those who participate in CALGB 80702 and are only receiving celecoxib/placebo) are eligible.", "Participants will be allowed to receive concomitant endocrine adjuvant therapy for breast cancer; however, all endocrine agents must be initiated at least one month prior to enrolment in the study and continue throughout the duration of participation in the study.", "Less than 120 minutes of exercise per week", "Approval by an oncologist or surgeon", "In English and able to read English", "No operations planned during the intervention period of 3 months", "At least one month after any major surgery at the beginning of the procedure, including the reversal of colostomy", "- Exclusion criteria:", "\u2022 Concurrent with other malignancies or history of other malignancies treated in the last 3 years (other than non-melanoma skin cancer or cervical cancer in situ)", "Metastatic diseases", "\u2022 Scheduled to receive any other form of adjuvant cancer treatment", "Currently on medicines for the treatment of diabetes", "Pregnant or breast-feeding", "Any condition associated with an increased risk of metformin-associated lactic acidosis (prior renal failure or hepatic impairment, history of any type of acidosis; usual consumption of 3 or more alcoholic beverages per day)", "Hypersensitivity or known intolerance to metformin"], "Results": ["Performance measures:", "Change in fasting insulin level", "Whether supervised exercise training alone and metformin, alone or in combination, can reduce fasting insulin levels from baseline to 3 months in patients who have completed standard I-III colorectal or breast cancer therapy. Insulin levels fasting in the blood will be calculated at baseline, 3 months and 6 months.", "Time limit: 0 to 3 months (change between 0 and 3 months)", "Results 1:", "Title of the arm/group: Exercise with Metformin", "Description of the arm/group: Exercise training with exercise physiologist with oral metformin", "\u2022 Exercise training plus metformin: Two supervised exercise sessions per week. QD oral metformin for 2 weeks, then IDB", "Total number of participants analysed: 33", "Average of least squares (standard error)", "Unit of measurement: mU/L -2,47 (1,07)", "Results 2:", "Title of the arm/group: Exercise training", "Description of the arm/group: Exercise training with an exercise physiologist", "Training: two supervised exercise sessions per week", "Total number of participants analysed: 34", "Average of least squares (standard error)", "Unit of measurement: mU/L -0.08 (1.06)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/35 (0.00 per cent)", "Adverse Events 2:", "Total: 0/35 (0.00 per cent)"]}